基于细胞的新冠病毒蛋白酶活性报告系统及药物筛选应用  

Cell-based Reporter Systems for SARS-CoV-2 Protease Activity and Its Application in Drug Screening

作　　者：董豹 陈月红 冯烨 姜涛 DONG Bao;CHEN Yuehong;FENG Ye;JIANG Tao(School of Basic Medical Sciences,Anhui Medical University,Hefei 230032,China;State Key Laboratory of Pathogen and Biosecurity,Academy of Military Medical Sciences,Academy of Military Sciences,Beijing 100071,China)

机构地区：[1]安徽医科大学基础医学院,合肥230032 [2]军事科学院军事医学研究院,病原微生物生物安全全国重点实验室,北京100071

出　　处：《病毒学报》2025年第1期211-221,共11页Chinese Journal of Virology

基　　金：病原微生物生物安全全国重点实验室面上项目(项目号:SKLPBS2209,SKLPBS2120)。

摘　　要：新型冠状病毒感染(Coronavirus disease 2019,COVID-19)是由新型冠状病毒(SARS-CoV-2)引起的全球暴发性传染病,严重危害人类的生命安全。为了遏制新型冠状病毒感染,研究学者致力于研发抗病毒药物。为快速直接评价抗新冠病毒药物的有效性,研究构建了多种新冠病毒的新型报告系统。本文综述了基于目前新冠病毒两种蛋白酶(Mpro和PLpro)切割功能的报告系统相关研究进展,及其在抗病毒药物研发中的应用。Coronavirus disease 2019(COVID-19),a disease caused by SARS-CoV-2,has given rise to a global pandemic and posed great threats to human health and safety.In response to this,the researchers have been actively engaged in the development of antiviral drugs to contain COVID-19 infections.A variety of new Covid-19 reporter systems have been developed for rapid and direct evaluation of the efficacy of anti-SARS-CoV-2 drugs.Herein,the progress of the reporter system based on the cleavage function of two proteases,Mpro and PLpro,of SARS-CoV-2 was reviewed and its applications in the research and development of antiviral drugs was discussed.

关 键 词：新冠病毒 蛋白酶 报告系统 抑制剂 抗病毒药物 

分 类 号：R373.1[医药卫生—病原生物学]